Last updated: 3 July 2019 at 3:30am EST

Kathryn L Biberstein Net Worth

The estimated Net Worth of Kathryn L Biberstein is at least 1.11 百万$ dollars as of 1 March 2018. Kathryn Biberstein owns over 9,250 units of Alkermes plc stock worth over 1,109,457$ and over the last 13 years Kathryn sold ALKS stock worth over 0$.

Kathryn Biberstein ALKS stock SEC Form 4 insiders trading

Kathryn has made over 47 trades of the Alkermes plc stock since 2011, according to the Form 4 filled with the SEC. Most recently Kathryn exercised 9,250 units of ALKS stock worth 245,773$ on 1 March 2018.

The largest trade Kathryn's ever made was exercising 39,500 units of Alkermes plc stock on 16 April 2013 worth over 480,320$. On average, Kathryn trades about 7,830 units every 42 days since 2011. As of 1 March 2018 Kathryn still owns at least 41,756 units of Alkermes plc stock.

You can see the complete history of Kathryn Biberstein stock trades at the bottom of the page.

What's Kathryn Biberstein's mailing address?

Kathryn's mailing address filed with the SEC is 850;852, Winter Street, Lincoln, Middlesex County, Massachusetts, 02451, United States.

Insiders trading at Alkermes plc

Over the last 13 years, insiders at Alkermes plc have traded over 407,046,771$ worth of Alkermes plc stock and bought 86,119 units worth 2,034,840$ . The most active insiders traders include Corp Plc Elan Science Three...、Richard F Pops、James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of 1,083,232$. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth 53,512$.

What does Alkermes plc do?

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

Complete history of Kathryn Biberstein stock trades at Alkermes plc

インサイダー	取引取引	合計金額
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	531,043$ 1 Mar 2018
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	217,950$ 26 Feb 2018
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	310,262$ 16 Feb 2018
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	89,803$ 15 Sep 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	191,688$ 11 Sep 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	216,375$ 28 May 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	239,250$ 3 Apr 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	100,004$ 10 Mar 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	213,395$ 3 Mar 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	343,333$ 1 Mar 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	198,675$ 26 Feb 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	198,675$ 26 Feb 2017
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	203,405$ 6 Dec 2016
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	215,700$ 22 Nov 2016
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	232,150$ 5 Oct 2016
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	172,988$ 28 May 2016
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	193,410$ 21 May 2016
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	263,139$ 20 Apr 2016
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	200,043$ 3 Mar 2016
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	126,038$ 26 Feb 2016
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	224,700$ 28 May 2015
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	512,325$ 20 May 2015
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	99,994$ 30 Mar 2015
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	254,800$ 3 Mar 2015
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	527,756$ 7 Jan 2015
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	229,952$ 5 Dec 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	100,001$ 26 Nov 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	223,500$ 11 Nov 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	298,000$ 6 Nov 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	104,243$ 30 Jun 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	103,320$ 17 Jun 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	171,525$ 28 May 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	362,835$ 20 May 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	136,219$ 17 May 2014
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	99,996$ 19 Dec 2013
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	138,338$ 18 Nov 2013
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	69,785$ 26 May 2013
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	143,910$ 21 May 2013
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	217,869$ 17 May 2013
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	480,320$ 16 Apr 2013
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	364,250$ 12 Apr 2013
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	104,685$ 31 Jan 2013
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	73,088$ 18 Nov 2012
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	34,298$ 26 May 2012
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	61,575$ 20 May 2012
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	52,219$ 17 May 2012
Kathryn L Biberstein SVP、GC (ゼネラルカウンセル)、参事、Alks、Inc.	オプション行使	56,250$ 18 Nov 2011

Alkermes plc executives and stock owners

Alkermes plc executives and other stock owners filed with the SEC include:

Richard Pops,
Chairman of the Board, Chief Executive Officer
Craig Hopkinson,
Executive Vice President, Research and Development and Chief Medical Officer
David Gaffin,
Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
James Frates,
Chief Financial Officer, Senior Vice President
Michael Landine,
Senior Vice President - Corporate Development, Chief Risk Officer
Richard F. Pops,
Chairman & CEO
Dr. Craig C. Hopkinson,
Exec. VP of R&D and Chief Medical Officer
David Joseph Gaffin,
Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
Frank Wilson,
Independent Director
Richard Gaynor,
Independent Director
Michael J. Landine,
Sr. VP of Corp. Devel. & Chief Risk Officer
Paul Mitchell,
Independent Director
Robert Breyer,
Independent Director
David Anstice,
Lead Independent Director
Nancy Snyderman,
Independent Director
Wendy Dixon,
Independent Director
Nancy Wysenski,
Independent Director
Shane Cooke,
Director
Iain Brown,
Senior Vice President - Finance, Chief Accounting Officer
Peter Norman,
Sr. VP of Policy & Gov. Relations
Iain Michael Brown,
Sr. VP & CFO
Dr. Floyd E. Bloom M.D.,
Founder
Stephen Schiavo,
Sr. VP of HR
Eva Stroynowski,
VP of Product & R&D Communications, Public Affairs
Sandra Coombs,
Co-Head of Investor Relations
Blair C. Jackson,
Exec. VP & COO
Dr. Floyd E. Bloom,
Founder
Floyd E Bloom,
Director
Elliot Ehrich,
SVP, R&D & CMO, Alkermes, Inc.
Mark Stejbach,
Chief Commercial Officer
James A. Jr. Robinson,
President & COO,Alkermes, Inc.
Nancy Lurker,
Director
Rebecca Peterson,
SVP, Corporate Communications
Geraldine Henwood,
Director
Kathryn L Biberstein,
SVP, GC, Secretary, Alks, Inc.
Gordon G Pugh,
SVP, COO & CRO, Alkermes, Inc.
James L Botkin,
SVP, Alkermes Gainesville LLC
Mark B Skaletsky,
Director
Corp Plc Elan Science Three...,
Christian Todd Nichols,
SVP, Chief Commercial Officer
Brian P Mckeon,
Director
David Angelo Jr. Daglio,
Director
Blair Curtis Jackson,
EVP, Chief Operating Officer
Emily Peterson Alva,
Director
Cato T Laurencin,
Director
Christopher I Wright,
Director
Samuel Joseph Parisi,
VP, Finance (Interim PAO)